Multidimensional multi-omics datasets from The Cancer Genome Atlas (TCGA), the Clinical Proteomic Tumor Analysis Consortium (CPTAC), and similar initiatives are becoming a powerful approach to understanding the molecular basis of disease and accelerating the translation of new discoveries to pati...
Next-generation mass spectrometry (NGMS) has become a powerful tool for protein identification and quantification from prospectively collected fresh frozen or optimal cutting temperature embedded specimens. However, limitations due to supply, accessibility, and delay of clinical information and o...
In biomedical research, sample mislabeling or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample transfe...
In recent years, proteomic technologies have emerged as invaluable tools in cancer research. Next-generation mass spectrometry (NGMS) is being used to study cancer biology, while providing the cancer research community with a growing body of biological knowledge that may lead to more effective dr...
Acute myeloid leukemia (AML) is a heterogenous malignancy that stems from the production of abnormal white blood cells, platelets, or red blood cells in the bone marrow. It is estimated that 19,520 new AML cases will occur in the United States this year.
In an effort to improve rigor and reproducibility, the National Cancer Institute (NCI) Antibody Characterization Program requests cancer-related protein targets for monoclonal antibody production and distribution to the scientific community. The program from The Office of Cancer Clinical Proteomi...
Eleven experts were interviewed in a series of videos titled Perspectives in Proteomics at the Human Proteome Organization World Congress (HUPO 2017) in Dublin, Ireland this past fall.
The National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research, part of the National Institutes of Health, along with the Indian Institute of Technology Bombay (IITB) and Tata Memorial Centre (TMC) have signed a Memorandum of Understanding (MOU) on clinical proteogenomics can...
In an effort to provide well-characterized monoclonal antibodies to the scientific community, the National Cancer Institute (NCI) Antibody Characterization Program requests cancer-related protein targets for affinity production and distribution.
An estimated 252,710 new cases of female breast cancer, accounting for 15% of all new cancer cases, occurred in 2017. To better understand proteogenomic abnormalities in breast cancer, the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) announces the release o...
Precision medicine is an approach that allows doctors to understand how a patient's genetic profile may cause cancer to grow and spread, leading to a more personalized treatment strategy based on molecular characterization of a person's tumor. However, precision medicine as a genomics-based appro...
Mutations in the RAS genes — KRAS, HRAS, and NRAS — have been identified in approximately 30% of all human cancers. While RAS gene family members encode proteins that are pivotal for cytoplasmic cell signaling, RAS oncogenes
Ionizing radiation (IR) is a commonly employed cancer treatment that kills cancer cells by damaging their DNA. While the DNA damage response (DDR) pathway may be key to determining tumor responses, radiochemical damage due to IR can target the patients’ healthy dividing cells, leading to the form...
The Office of Cancer Clinical Proteomics Research at the National Cancer Institute, part of the United States National Institutes of Health, is spearheading the preparationand training of the proteogenomic research workforce on an international scale.
Breast cancer is the second most common cancer in women living in the United States, with triple-negative breast cancer (TNBC) accounting for approximately 15% of diagnoses. While chemotherapy is the standard-of-care in TNBC, resistance is common and associated with poor prognosis.
A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying diagnostics and therapies that will improve patients’ lives. Because a comprehensive molecular view of cancer is important for ultimately guiding treatment, the National Cancer Institute (NCI)...
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce that teams led by Jaewoo Kang (Korea University), and Yuanfang Guan with Hongyang Li (University of Michigan) as the best performers of the NCI-CPTAC DREAM Proteogenomics Computational...
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) announces the release of the cancer proteome confirmatory colon study data. The goal of the study is to analyze the proteomes of approximately 100 confirmatory colon tumor patients, which includes tumor and a...
Liquid chromatography tandem-mass spectrometry (LC-MS/MS)- based methods such as isobaric tags for relative and absolute quantification (iTRAQ) and tandem mass tags (TMT) have been shown to provide overall better quantification accuracy and reproducibility over other LC-MS/MS techniques. However,...
Multi-omics analysis has grown in popularity among biomedical researchers given the comprehensive characterization of thousands of molecular attributes in addition to clinical attributes. Several data portals have been devised to make these datasets directly available to the cancer research commu...